We validated our single-nucleus RNA sequencing findings in an expanded cohort of AD cases demonstrating that APOE and TREM2 risk variants are associated with a significant reduction in CD163-positive amyloid-responsive microglia. This evidence concerns the gene TREM2 and Alzheimer disease.